J Pathol:单胺氧化酶A(MAOA)在经典型霍奇金淋巴瘤中高表达。

2017-07-24 fengxiangxin MedSci原创

单胺氧化酶A(MAOA)是一种线粒体酶,研究表明它能够促进胶质瘤和前列腺癌的进展,但其表达和功能相关性的研究尚未在淋巴瘤中被开展。

单胺氧化酶A(MAOA)是一种线粒体酶,研究表明它能够促进胶质瘤和前列腺癌的进展,但其表达和功能相关性的研究尚未在淋巴瘤中被开展。

研究者评估了427例霍奇金淋巴瘤和非霍奇金淋巴瘤的MAOA,同时也通过福尔马林固定石蜡包埋的标本免疫组化分析后得到的反应性淋巴组织谱对MAOA进行了评估。结果发表于最新一期的《J Pathol》上。

相比EBV阳性的经典型霍奇金淋巴瘤(cHL),EBV阴性的cHL中MAOA较常见(P?<?0.0001),尤其在EBV阴性的结节硬化型cHL中。类似于人类淋巴瘤组织,大多数经典型霍奇金淋巴瘤(cHL)来源的细胞系显示出了MAOA活性,而非霍奇金淋巴瘤来源的细胞系却没有。

MAOA抑制剂clorgyline抑制了L1236细胞和U-HO1 细胞的生长,敲除shRNA的MAOA 抑制了L1236细胞的生长。相反,MAOA的异常过表达促进了MAOA阴性的HDLM2细胞的生长。clorgyline和ABVD(阿霉素、博来霉素、长春碱、氮烯唑胺)的联合应用相比两者单独应用时的细胞生长抑制效果更明显。

总之,MAOA在经典霍奇金淋巴瘤(cHL)中高表达,并能够反映出淋巴瘤不同的生物学特性。针对MAOA作为一个新的诊断指标和治疗靶点的潜在效用开展进一步的研究是十分有必要的。

原始出处:

Li, P.C., I.N. Siddiqi, A. Mottok, et al., Monoamine Oxidase A is Highly Expressed in Classical Hodgkin Lymphoma. 2017.

本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786181, encodeId=67a41e86181e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 28 04:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305493, encodeId=dbd130549328, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Apr 13 21:49:51 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226057, encodeId=37e722605e35, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jul 25 07:28:30 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226023, encodeId=6a6f2260230b, content=学习并分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jul 25 06:40:57 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225882, encodeId=3a4c22588248, content=精准医学时代到来的基础, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Jul 24 18:52:27 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2018-05-28 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786181, encodeId=67a41e86181e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 28 04:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305493, encodeId=dbd130549328, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Apr 13 21:49:51 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226057, encodeId=37e722605e35, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jul 25 07:28:30 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226023, encodeId=6a6f2260230b, content=学习并分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jul 25 06:40:57 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225882, encodeId=3a4c22588248, content=精准医学时代到来的基础, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Jul 24 18:52:27 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2018-04-13 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1786181, encodeId=67a41e86181e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 28 04:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305493, encodeId=dbd130549328, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Apr 13 21:49:51 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226057, encodeId=37e722605e35, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jul 25 07:28:30 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226023, encodeId=6a6f2260230b, content=学习并分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jul 25 06:40:57 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225882, encodeId=3a4c22588248, content=精准医学时代到来的基础, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Jul 24 18:52:27 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2017-07-25 189****7206

    学习了受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1786181, encodeId=67a41e86181e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 28 04:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305493, encodeId=dbd130549328, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Apr 13 21:49:51 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226057, encodeId=37e722605e35, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jul 25 07:28:30 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226023, encodeId=6a6f2260230b, content=学习并分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jul 25 06:40:57 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225882, encodeId=3a4c22588248, content=精准医学时代到来的基础, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Jul 24 18:52:27 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2017-07-25 大爰

    学习并分享!!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1786181, encodeId=67a41e86181e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 28 04:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305493, encodeId=dbd130549328, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Apr 13 21:49:51 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226057, encodeId=37e722605e35, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jul 25 07:28:30 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226023, encodeId=6a6f2260230b, content=学习并分享!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jul 25 06:40:57 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225882, encodeId=3a4c22588248, content=精准医学时代到来的基础, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Jul 24 18:52:27 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2017-07-24 fengxiangxin301

    精准医学时代到来的基础

    0

相关资讯

Blood:RS细胞中表达的PIM激酶如何影响霍奇金淋巴瘤细胞的免疫特性和存活?

典型霍奇金淋巴瘤(cHL)中的RS细胞表达多种免疫调节蛋白,形成cHL的微环境使得肿瘤细胞能够免疫逃逸。特定免疫调节蛋白的表达受促存活转录因子(如NFκB和STATs)调节。鉴于促存活转录因子还可以诱导致瘤性PIM1/2/3丝氨酸/苏氨酸激酶的表达,并且PIMs还能够调节NFκB和STATs的转录活性,Maciej Szydlowski及其同事猜测上述激酶有助于RS细胞存活和协助其免疫逃逸。研究人

Blood:使用含蒽环类药物化疗结合化疗增加霍奇金淋巴瘤生存者罹患心脏衰竭概率3倍

这项研究说明了,治疗霍奇金淋巴瘤所使用的心脏放疗和使用含蒽环类药物的化疗对于霍奇金淋巴瘤生存者罹患心脏衰竭的几率有很大作用。放疗辐射剂量大于20Gy会明显提高心脏衰竭的几率。单单使用含蒽环类药物的化疗增加了3倍的罹患心脏衰竭的几率。为在临床中选择适当的放化疗剂量提供了参考

J Clin Oncol:pembrolizumab治疗复发难治的经典型霍奇金淋巴瘤有疗效

经典型霍奇金淋巴瘤(cHL)是一种治愈率很高的肿瘤,但对于放化疗难治或治疗后复发的患者,缺乏有效的治疗方案。cHL的肿瘤细胞-霍奇金Reed-Sternberg(HRS)细胞常具有染色体9p24.1的异常,这使得PD-1分子的配体PD-L1和PD-L2异常高表达,这些为在复发难治的cHL使用PD-1抑制剂提供了遗传学基础。KEYNOTE-087临床试验探索了pembrolizumab治疗复发难治的

盘点:近期霍奇金淋巴瘤治疗进展

霍奇金淋巴瘤(HL)是起源于淋巴造血系统恶性肿瘤,依据临床及病理学差异分为经典霍奇金淋巴瘤(cHL)及结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL),其中前者占HL中95%。发病原因尚不明确,但至今未发现其风险因素,如免疫系统抑制和暴露于某些感染。早期症状包括腋窝、颈部和腹股沟淋巴结肿大,伴有发热、胸痛、盗汗、体重减轻等。 【1】Lancet Oncol:年轻霍奇金淋巴瘤幸存者其心血

Br J Haematol:霍奇金淋巴瘤和非霍奇金淋巴瘤长期存活者的继发性恶性肿瘤

2017年4月,发表在《Br J Haematol》的一项由德国科学家进行的德国癌症注册数据的汇总分析(1990~2012),考察了霍奇金淋巴瘤和非霍奇金淋巴瘤长期存活者的继发性恶性肿瘤。

2016NCCN肿瘤学临床实践指南:霍奇金淋巴瘤(2016年第2版)发布

2016 NCCN肿瘤学临床实践指南:霍奇金淋巴瘤(2016年第2版)-中文翻译版对应指南:NCCN临床实践指南:霍奇金淋巴瘤(2016.V2)美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)